A5038857620- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Disaster Response and Management
- Hepatitis B Virus Studies
- SARS-CoV-2 and COVID-19 Research
- Fire effects on ecosystems
- Global Security and Public Health
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- Rabies epidemiology and control
- Healthcare Systems and Practices
- Zoonotic diseases and public health
- Yersinia bacterium, plague, ectoparasites research
- Vector-Borne Animal Diseases
- Mosquito-borne diseases and control
- Social Policies and Family
- Virology and Viral Diseases
Le Laboratoire P4 Inserm Jean Mérieux
2012-2024
Inserm
2012-2024
Institut Pasteur
2004-2014
Ekaterinburg Research Institute of Viral Infections
2014
Université Claude Bernard Lyon 1
2011
Fondation Mérieux
2004
In March 2014, the World Health Organization was notified of an outbreak a communicable disease characterized by fever, severe diarrhea, vomiting, and high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as causative agent. Full-length genome sequencing phylogenetic analysis showed that EBOV from Guinea forms separate clade relationship to known strains Democratic Republic Congo Gabon. Epidemiologic linked laboratory-confirmed cases with presumed first...
Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the outbreak was at its peak, World Health Organization released short list of drugs suitable EVD research. Favipiravir, an antiviral developed severe influenza, one these. late conditions starting randomized trial were not fulfilled two reasons. One perception that, given high number patients presenting simultaneously and very mortality rate disease, it...
Crimean–Congo haemorrhagic fever (CCHF), a potentially severe zoonotic viral disease causing and manifestations in humans. As the virus (CCHFV) has been detected ticks Spain antibodies against ruminant sera Corsica, it was necessary to know more about situation France. In 2022–2023, CCHFV 155 collected from horses cattle southern
Abstract Lassa fever is a hemorrhagic caused by virus (LV), an old-world Arenavirus. Little known about the immune responses that occur during disease, but protection seems to be linked induction of cellular specific for viral glycoproteins. Conversely, severe may associated with immunosuppression. We studied infection human dendritic cells (DC) and macrophages (MP) LV. Both these cell types are susceptible LV infection. Viral nucleoprotein was detected in DC MP, high moderate titers were...
BACKGROUND. The pathogenesis of Ebola virus (EBOV) disease (EVD) is poorly characterized. establishment well-equipped diagnostic laboratories close to treatment centers (ETCs) has made it possible obtain relevant virological and biological data during the course EVD assess their association with clinical different outcomes disease. METHODS. We were responsible for diagnosing EBOV infection in patients admitted two ETCs forested areas Guinea. pattern signs was recorded, an etiological...
ABSTRACT The events leading to death in severe cases of Lassa fever (LF) are unknown. Fatality seems be linked high viremia and immunosuppression, cellular immunity, rather than neutralizing antibodies, appears essential for survival. We previously compared virus (LV) with its genetically close but nonpathogenic homolog Mopeia (MV), which was used model nonfatal LF. showed that strong early activation antigen-presenting cells (APC) may play a crucial role controlling infection. Here we...
The 2013-16 Ebola virus disease epidemic in west Africa caused international alarm due to its rapid and extensive spread resulting a significant death toll social unrest within the affected region. large number of cases provided an opportunity study long-term kinetics Zaire ebolavirus-specific immune response survivors addition known contacts those infected with virus.
We report two outbreaks of Lassa fever that occurred in Benin 2014 and 2016 with 20 confirmed cases 50% (10/20) mortality. was not previously considered to be an endemic country for fever, resulting a delay diagnose the disease its human transmission. Molecular investigations showed viral genomes similar Togo strain, which is genetically very different from other known strains confirms existence new lineage. Endemic circulation virus territory genetic diversity thus confirm this represents...
Lassa virus (LV) and Mopeia (MV) are closely related members of the Arenavirus genus, sharing 75% amino acid sequence identity. However, LV causes hemorrhagic fever in humans nonhuman primates, whereas MV cannot induce disease. We have previously shown that antigen-presenting cells (APC)-macrophages (MP) dendritic (DC)-sustain high replication rates but not activated, suggesting they play a role immunosuppression observed severe cases fever. Here, we infected human APC with analyzed cellular...
Hemorrhagic fever outbreaks are difficult to diagnose and control in part because of a lack low-cost easily accessible diagnostic structures countries where etiologic agents present. Furthermore, initial clinical symptoms common shared with other endemic diseases such as malaria or typhoid fever. Current molecular methods polymerase chain reaction require trained personnel laboratory infrastructure, hindering diagnostics at the point need, particularly outbreak settings. Therefore, rapid...
Crimean-Congo haemorrhagic fever (CCHF) is an infectious viral disease that has (re-)emerged in the last decade south-eastern Europe, and there a risk for further geographical expansion to western Europe. Here we report results of survey covering 28 countries, conducted 2012 among member laboratories European Network Diagnostics 'Imported' Viral Diseases (ENIVD) assess laboratory preparedness response capacities CCHF. The answers 31 region regarding CCHF case definition, training necessity,...
Sudan ebolavirus (SUDV) is one of four members the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which characterized by hemorrhagic fever and a high case fatality rate. While licensed therapeutics vaccines are available limited number treat infections Zaire ebolavirus, there currently no effective or for SUDV. A well-characterized animal model this disease needed further development testing therapeutics. In study, twelve cynomolgus macaques (Macaca fascicularis) were...
Ebola virus (EBOV) haemorrhagic fever remains a threat to global public health with an urgent need for effective treatment. In order achieve these goals, access non-human primate (NHP) laboratory models is essential requirement. Here, we present the first NHP-EBOV model readily available European scientific community, based on infection of Mauritian cynomolgus macaques using Central-African EBOV strain and increasing challenge dose (10, 100, or 1000 focus forming units per animal). The...
The pathogenesis of Lassa fever (LF), a hemorrhagic endemic to West Africa, remains unclear. We previously compared virus (LASV) with its genetically close, but nonpathogenic homolog Mopeia (MOPV) and demonstrated that the strong activation antigen-presenting cells (APC), including type I IFN production, observed in response MOPV probably plays crucial role controlling infection. show here human macrophages (MP) produce large amounts CC CXC chemokines infection, whereas dendritic (DC)...
Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for treatment acute EBOV disease (EVD). In response to 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results guinea pig model infection, EBOTAb tested cynomolgus macaque non-human primate lethal infection. To ensure stringent therapeutic testing conditions replicate...
There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab')2, EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola antibodies high neutralization activity. Highly purified equine F(ab')2 showed strong cross-neutralization 2 Zaire EBOV strains (Gabon 2001 and Makona) in vivo 3 5 daily intraperitoneal injections provided...
Abstract Background Ebola (EBOV) and Sudan (SUDV) orthoebolaviruses are responsible for lethal hemorrhagic fever outbreaks in humans Central West Africa, apes that can be at the source of human EBOV. Methods To assess risk exposure to through contact with nonhuman primates (NHP), we tested presence antibodies against different viral proteins a microsphere-based multiplex immunoassay case-control study on bites from NHPs forest areas Cameroon (n = 795) cross-sectional surveys other rural...
SUMMARY Introduction An unprecedented outbreak of Ebola virus diseases (EVD) occurred in West Africa from March 2014 to January 2016. The French Institute for Public Health implemented strengthened surveillance early identify any imported case and avoid secondary cases. Methods Febrile travellers returning an affected country had report the national emergency healthcare hotline. Patients reporting at-risk exposures fever during 21st following day last exposure were defined as possible cases,...
Lassa fever is a hemorrhagic endemic to West Africa and caused by virus, an Old-World arenavirus. It may be fatal, but most patients recover from acute disease some experience asymptomatic infection. The immune mechanisms associated with these different outcomes have not yet been fully elucidated, considerable progress has recently made, through the use of in vitro human models non-human primates, only relevant animal model that mimics pathophysiology responses induced patients. We discuss...